Table 3 Cost-utility results
From: Cost-utility analysis of genomic profiling in early breast cancer in Colombia
Chemotherapy (ChT) | Oncotype DX™ (ODX) | Mammaprint™ (MMP) | |
|---|---|---|---|
LY | 4.36 | 4.33 | 4.34 |
QALY | 3.75 | 3.81 | 3.79 |
Costs | $13,446 | $11,071 | $12,892 |
Incremental LY | |||
Test vs. ChT | − 0.03 | − 0.02 | |
ODX vs. MMP | − 0.01 | ||
Incremental QALY | |||
Test vs. ChT | 0.06 | 0.03 | |
ODX vs. MMP | 0.03 | ||
Incremental cost | |||
Test vs. QT | − $2375 | − $554 | |
ODX vs. MMP | − $1821 | ||
ICUR (per QALY) | |||
Test vs. QT | Dominant | Dominant | |
ODX vs. MMP | Dominant | ||
Incremental NMB (per QALY) | |||
Test vs. ChT | $2751 | $755 | |
ODX vs. MMP | $1996 | ||